All In Biotech

Free tool

FAERS Monitor: Belsomra

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 204569 or its brand name (Belsomra, Suvorexant). Reports on generic versions are filed under their own applications.

Reports

13,031

Serious

4,515

35% of reports

Hospitalization

2,057

Death reported

718

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective3,050
  • nightmare743
  • somnolence738
  • insomnia688
  • abnormal dreams603
  • headache549
  • feeling abnormal489
  • nausea395
  • no adverse event389
  • hallucination380
  • fatigue365
  • dizziness341
  • anxiety317
  • off label use275
  • fall272

Reports by year received

View as table
YearReports
201413
20152,481
20162,499
20172,016
20181,159
2019926
2020783
2021714
2022600
2023602
2024492
2025417
2026329

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,041,128 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
abnormal dreamsSignal60336.033.320,070
nightmareSignal74335.433.024,309
hallucinationSignal3808.27.42,382
somnolenceSignal7385.95.53,041
insomniaSignal6884.23.91,677
drug ineffectiveSignal3,0503.73.66,519
no adverse eventSignal3893.53.1686
feeling abnormalSignal4893.33.0788
anxiety3171.81.6113
headache5491.41.368
fall2721.31.221
dizziness3411.11.03
nausea3950.80.719
fatigue3650.80.729
off label use2750.50.5137

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.